Malignant Mesothelioma: Has Anything Changed?

Kim, Roger Y.; Sterman, Daniel H.; Haas, Andrew R.

doi:10.1055/s-0039-1693406

Cited by 24 publications

(23 citation statements)

References 147 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This multidrug chemotherapy may indeed have immunosuppressive effects by affecting essential components of host immunity. On the contrary, the new regimen may induce immunogenic cell death and improve immunotherapy based on immune checkpoint inhibitors [ 41 , 42 ]. The rationale of this combinatorial approach is supported by accumulating evidence indicating that chemotherapy regulates the composition and function of tumor infiltrating lymphoid and myeloid cells [ 43 , 44 ].…”

Section: Discussionmentioning

confidence: 99%

TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma

Staumont

Jamakhani

Costa

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: There is no standard chemotherapy for refractory or relapsing malignant pleural mesothelioma (MPM). Our previous reports nevertheless indicated that a combination of an anthracycline (doxorubicin) and a lysine deacetylase inhibitor (valproic acid, VPA) synergize to induce the apoptosis of MPM cells and reduce tumor growth in mouse models. A Phase I/II clinical trial indicated that this regimen is a promising therapeutic option for a proportion of MPM patients. Methods: The transcriptomes of mesothelioma cells were compared after Illumina HiSeq 4000 sequencing. The expression of differentially expressed genes was inhibited by RNA interference. Apoptosis was determined by cell cycle analysis and Annexin V/7-AAD labeling. Protein expression was assessed by immunoblotting. Preclinical efficacy was evaluated in BALB/c and NOD-SCID mice. Results: To understand the mechanisms involved in chemoresistance, the transcriptomes of two MPM cell lines displaying different responses to VPA-doxorubicin were compared. Among the differentially expressed genes, transforming growth factor alpha (TGFα) was associated with resistance to this regimen. The silencing of TGFα by RNA interference correlated with a significant increase in apoptosis, whereas the overexpression of TGFα desensitized MPM cells to the apoptosis induced by VPA and doxorubicin. The multi-targeted inhibition of histone deacetylase (HDAC), HER2 and TGFα receptor (epidermal growth factor receptor/EGFR) improved treatment efficacy in vitro and reduced tumor growth in two MPM mouse models. Finally, TGFα expression but not EGFR correlated with patient survival. Conclusions: Our data show that TGFα but not its receptor EGFR is a key factor in resistance to MPM chemotherapy. This observation may contribute to casting light on the promising but still controversial role of EGFR signaling in MPM therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma

Staumont

Jamakhani

Costa

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Za dijagnostiku malignog mezotelioma potrebno je dobiti uzorak pleuralnog izljeva i/ili bioptirati lezije pleure kako bi se dobilo tkivo za patohistološku analizu 10 . Neki od dijagnostičkih postupaka jesu torakocenteza, biopsija širokom iglom (engl.…”

Section: Patohistološka I Citološka Dijagnostikaunclassified

“…Neki od dijagnostičkih postupaka jesu torakocenteza, biopsija širokom iglom (engl. core needle biopsy), torakoskopska biopsija te otvorena biopsija pleure 10 . Prognoza bolesti poboljšava se ukoliko je dijagnoza MMP-a postavljena u što ranijoj fazi bolesti, uz posljedično raniji početak liječenja.…”

Section: Patohistološka I Citološka Dijagnostikaunclassified

Novosti u dijagnostici malignog mezotelioma pleure

Murković

Benvin

Štemberger

et al. 2021

Med. Flum. (Online)

View full text Add to dashboard Cite

Maligni mezoteliom (MM) pleure agresivna je maligna bolest čija je incidencija u porastu. Dijagnostika MM-a izazovna je zbog kasnog javljanja simptoma bolesti, a problem predstavljaju poteškoće razlikovanja benignih i malignih lezija što ponekad odgađa dijagnozu. Slikovna procjena najčešće se provodi CT (engl. Computed tomography) dijagnostikom, dok se konačna dijagnoza uspostavlja nakon biopsije i analize patohistološkog uzorka. Dijagnozu epiteloidnog mezotelioma moguće je uspostaviti citološkom analizom pleuralnog izljeva, gdje su potrebna dva pozitivna imunocitokemijska markera koji potvrđuju dijagnozu te dva negativna markera koji isključuju dijagnozu. Cilj je ovog rada prikazati trenutna saznanja o slikovnim, citološkim i patohistološkim metodama dijagnosticiranja MM-a.

show abstract

“…Doll et al, have linked the lung cancer diagnosis of a group of workers with their past asbestos exposure [6]. It has been well established that exposure to mineral fibers such as asbestos and erionite is the main cause of MPM [7]. Asbestos is the commercial umbrella term for six types of naturally occurring silicate fibers, all of which have been considered as carcinogenic to humans by International Agency for Research on Cancer (IARC) [8].…”

Section: Introductionmentioning

confidence: 99%

Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review

Töreyin

Ghosh

Göksel

et al. 2020

IJERPH

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is mainly related to previous asbestos exposure. There is still dearth of information on non-invasive biomarkers to detect MPM at early stages. Human studies on exhaled breath biomarkers of cancer and asbestos-related diseases show encouraging results. The aim of this systematic review was to provide an overview on the current knowledge about exhaled breath analysis in MPM diagnosis. A systematic review was conducted on MEDLINE (PubMed), EMBASE and Web of Science databases to identify relevant studies. Quality assessment was done by the Newcastle–Ottawa Scale. Six studies were identified, all of which showed fair quality and explored volatile organic compounds (VOC) based breath profile using Gas Chromatography Coupled to Mass Spectrometry (GC–MS), Ion Mobility Spectrometry Coupled to Multi-capillary Columns (IMS–MCC) or pattern-recognition technologies. Sample sizes varied between 39 and 330. Some compounds (i.e, cyclohexane, P3, P5, P50, P71, diethyl ether, limonene, nonanal, VOC IK 1287) that can be indicative of MPM development in asbestos exposed population were identified with high diagnostic accuracy rates. E-nose studies reported breathprints being able to distinguish MPM from asbestos exposed individuals with high sensitivity and a negative predictive value. Small sample sizes and methodological diversities among studies limit the translation of results into clinical practice. More prospective studies with standardized methodologies should be conducted on larger populations.

show abstract

Malignant Mesothelioma: Has Anything Changed?

Cited by 24 publications

References 147 publications

TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma

TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma

Novosti u dijagnostici malignog mezotelioma pleure

Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review

Contact Info

Product

Resources

About